Kura Oncology, Inc.

Healthcare

NASDAQ:KURA · NASDAQ Global Select

Market Cap $803.41M Beta 0.36 P/E (TTM) -2.7

$9.05 +2.14%

+$0.19 today

52W Low $5.45High $12.49

Vol 1.29M · Avg 2.09M

EPS (TTM)-$3.32

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+40.53%

Period High

$12.14

Period Low

$5.54

Latest

$9.05

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Tango Therapeutics, Inc.

NASDAQ:TNGX

$3.59B

Tyra Biosciences, Inc.

NASDAQ:TYRA

$1.61B

Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

$1.19B

EyePoint Pharmaceuticals, Inc.

NASDAQ:EYPT

$1.09B

Savara Inc.

NASDAQ:SVRA

$1.08B

Replimune Group, Inc.

NASDAQ:REPL

$733.24M

Maravai LifeSciences Holdings, Inc.

NASDAQ:MRVI

$722.58M

Prime Medicine, Inc.

NASDAQ:PRME

$501.21M

Rezolute, Inc.

NASDAQ:RZLT

$385.17M

ProKidney Corp.

NASDAQ:PROK

$242.99M

What is the latest KURA filing?

The latest filing shown is 4 dated Jun 4, 2026.

How many recent filings does KURA have?

Intrinsic Alpha currently shows 20 recent filings for KURA.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.